Compare Bristol-Myers Squibb Co (BMY) vs Iris Energy Limited (IREN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Iris Energy Limited — how do they compare? Bristol-Myers Squibb Co trades at $58.52 (market cap $116.30B), while Iris Energy Limited trades at $38.49 (market cap $13.80B). The key difference: Bristol-Myers Squibb Co is far larger — about 8.4× Iris Energy Limited's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Iris Energy Limited pays none. Which is the better fit depends on your goals.
| BMY | IREN | |
|---|---|---|
Market Cap | $116.30B | $13.80B |
Sector | Health | Energy |
52-Week High | $62.37 | $76.41 |
52-Week Low | $42.60 | $15.40 |
Enterprise Value | $152.24B | $15.55B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
IREN trades at $38.98, down 5.18% on the day, amid a bearish technical signal and recent earnings misses. The company is transitioning from Bitcoin mining to AI infrastructure, showing strong revenue growth projections for 2026 ($757M) and a net income margin improvement to 20.87%. However, negative ROE and ROA highlight profitability challenges. Analyst consensus remains bullish with a $79.11 price target, but high valuation ratios (P/E 50.14, P/S 14.99) suggest premium pricing.
The outlook hinges on successful execution of AI cloud expansion, with key risks including competitive pressures from Meta's cloud ambitions and operational scalability. Investors face a high-risk, high-reward scenario, balancing analyst optimism against technical weakness and recent stock volatility. Near-term catalysts include potential contracts and capacity milestones, but misses on earnings expectations warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Iris Energy Limited
Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.
Read more on IREN →
